Phase 1 Stem Cell Clinical Trials
30 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 30 trials
Recruiting
Phase 1Phase 2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
University of Colorado, Denver24 enrolled4 locationsNCT07252050
Recruiting
Phase 1
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.75 enrolled6 locationsNCT06452316
Recruiting
Phase 1Phase 2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Phase 1
Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT
Chronic PancreatitisMesenchymal Stem Cells
Medical University of South Carolina42 enrolled1 locationNCT05095532
Recruiting
Phase 1Phase 2
Immune Tolerance Induction After Liver Transplantation
Liver TransplantationEnd Stage Liver DiseaseImmune Tolerance+6 more
University of California, Los Angeles12 enrolled1 locationNCT07269041
Recruiting
Phase 1Phase 2
Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis
Mesenchymal Stem CellsSclerosis, Systemic
Marie Hudson, MD18 enrolled1 locationNCT04356287
Recruiting
Phase 1
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)
Children's National Research Institute48 enrolled3 locationsNCT04691622
Recruiting
Phase 1
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
Hematopoietic Stem Cell Transplantation
Children's Hospital Medical Center, Cincinnati20 enrolled1 locationNCT07375290
Recruiting
Phase 1Phase 2
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 1Phase 2
Donor-Derived Viral Specific T-cells (VSTs)
Viral reactivationallogeneic stem cell transplantViral Infection
Children's Hospital Medical Center, Cincinnati750 enrolled3 locationsNCT02048332
Recruiting
Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
Hematopoietic and Lymphoid Cell NeoplasmAllogeneic Hematopoietic Stem Cell Transplant Recipient
City of Hope Medical Center53 enrolled1 locationNCT04177004
Recruiting
Phase 1
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 1
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
EfficacySafetySpinal Cord Injury+4 more
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.12 enrolled1 locationNCT06976229
Recruiting
Phase 1
IS-free Treg HaploHCT
Myelodysplastic SyndromesStem Cell Transplant ComplicationsGraft vs Host Disease+2 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Phase 1
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Hematologic MalignancyGvHDGVHD,Acute+8 more
Tr1X, Inc.36 enrolled5 locationsNCT06462365
Recruiting
Phase 1
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
Hematologic MalignancyHaplo-identical Stem Cell Transplantation
University Hospital, Geneva12 enrolled1 locationNCT05066412
Recruiting
Phase 1Phase 2
HUC-MSC for Treatment of High-risk HPV Infection
Human Papillomavirus VirusesMesenchymal Stem Cells
Shanghai East Hospital60 enrolled1 locationNCT06610773
Recruiting
Phase 1
Phase I trial of multi-virus-specific T cells for paediatric haploidentical -stem cell transplant recipients
Haplo-identical haematopoietic stem cell transplantation
QIMR Berghofer Medical Research Institute20 enrolled1 locationACTRN12620000141943
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001501134
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001492145